From: Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets
Total No. affected individual | 14 |
---|---|
Age (mean ± S.D. (range)) | 53 ± 30 (23–75) |
Gender | |
 Female | 5 (35.7%) |
 Male | 9 (64.3%) |
Tumor size | |
 0-5 cm | 5 (35.7%) |
 5-10 cm | 6 (42.9%) |
 10-15 cm | 3 (21.4%) |
Grade (FNCLCC) | |
 I | 1 (7.1%) |
 II | 4 (28.6%) |
 III | 9 (64.3%) |
Primary site | |
 Upper extremity | 2 (14.3%) |
 Lower leg | 2 (14.3%) |
 Thigh | 9 (64.3%) |
 Pelvis | 1 (7.1%) |
Stage at time of sample procurement | |
 Primary | 9 (64.3%) |
 Local recurrence | 3 (21.4%) |
 Distant recurrence | 2 (14.3%) |
Histology | |
 Myxofibrosarcoma | 3 (21.4%) |
 Leiomyosarcoma | 5 (35.7%) |
 Undifferentiated sarcoma | 6 (42.9%) |
 Undifferentiated pleomorphic sarcoma | 4 (28.6%) |
 Undifferentiated round cell sarcoma | 1 (7.1%) |
 Undifferentiated spindle cell sarcoma | 1 (7.1%) |
Pre-operative Therapy | |
 None | 11 (78.6%) |
 Pre-operative Chemotherapy | 2 (14.3%) |
 Pre-operative Radiation-Therapy | 0 (0.0%) |
 Both | 1 (7.1%) |
 Median follow-up | 42.29 months |
Time to relapse | |
 Local recurrence | 2.0 months |
 Distant recurrence | 6.1 months |